Ashwin here again 👋 — CTO and co-founder of Biostate AI.

In our last update, I shared what Biostate AI is and how we’re building a future where diseases can be predicted—not just treated.

Now let me tell you about one of the most exciting things we’re doing right now…

Our Partnership with the Accelerated Cure Project (ACP)

We’ve teamed up with ACP, one of the leading non-profits in multiple sclerosis (MS) research, to analyze clinical MS samples using our proprietary BIRT RNASeq technology.

This is a big deal.

Why?

Because MS is a complex disease with no cure and limited treatment personalization—but through RNA, our AI can spot patterns that researchers have never seen before.

✅ We’re sequencing 100 real clinical MS samples

✅ Our tech does this at 5X lower cost than standard RNA sequencing

✅ This means more data, faster insights, and new paths to treatment

This isn’t just theory—it’s real science, real patients, and real-world validation of what we’re building.

And it’s just the beginning.

What Happens When We Scale This?

What if we could do this for millions of samples—across hundreds of diseases?

That’s where Biostate AI is heading.

But here’s the thing…

⏳ Our Public Raise Is Closing Soon

This is the final month we’re letting everyday investors join us.

We’ve raised over $8M so far—but once we close, the round is done.

If you’ve been waiting, this is your moment.

🔴 Invest now on Wefunder before the round closes

In the next update, I’ll walk you through how our AI is being trained—and how this gives us a long-term advantage no one else has.

Talk soon,

– Ashwin Gopinath

CTO, Biostate AI